Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease

Annals of Nuclear Medicine

Volumn 27, Issue 5, 2013, Pages 444-451

  Chiaravalloti, Agostino ^a   Stefani, Alessandro ^a   Di Biagio, Daniele ^a   Pierantozzi, Mariangela ^a   Tavolozza, Mario ^a   Di Pietro, Barbara ^a   Stanzione, Paolo ^a   Schillaci, Orazio ^a,b  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

DAT SCAN; Dopamine transporter; MIBG; Noradrenergic system; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; N (3 FLUOROPROPYL) 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AKINESIA; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG UPTAKE; FEMALE; GAMMA CAMERA; HEART DENERVATION; HEART SCINTISCANNING; HUMAN; MALE; MEDIASTINUM; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATONIGRAL DEGENERATION; TREMOR;

AUTONOMIC NERVOUS SYSTEM DISEASES; CORPUS STRIATUM; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SUBSTANTIA NIGRA; SYMPATHECTOMY;

EID: 84879012692     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-013-0702-z     Document Type: Article

References (30)

1. Brooks DJ, Pavese N. Imaging non-motor aspects of Parkinson's disease. Prog Brain Res. 2010;184:205-18.
2. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;381:121-34.
3. Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. In: Mardsen CD, Faha S, editors. Movement disorders 2. London: Butterwoths; 1987.
4. Chaudhri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5:235-45.
5. Somsen GA, Verberne HJ, Fleury E, Righetti A. Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies. J Nucl Cardiol. 2004;11:126-33.
6. Marek K, Jennings D, Seibyl J. Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease. Adv Neurol. 2003;91:183-91.
7. Hughes A, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;66:181-4.
8. Movement Disorder Society. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Movement disorders. 2003;18:738-50. doi: 10.1002/mds.10473.
9. Spiegel J, Hellwing D, Samnick S, Jost W, Mollers M, Fassbender K, et al. Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. J Neural Tansm. 2007;114:331-5.
10. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992;14:513-21.
11. Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc JL, et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord. 2003;18:890-7.
12. Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS, et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using 123I-labelled dopamine transporter ligands. Eur J Nucl Med Mol Imaging. 2002;29:30-5.
13. Chang LT. A method for attenuation correction in radio nuclide computed tomography. IEEE Trans Nucl Sci. 1978;25:638-43.
14. Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, et al. Practical benefit of 123I-FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med. 1997;24:68-71.
15. Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with (123)I-FP-CIT in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging. 2005;32:1452-6.
16. Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131I/123I-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:2436-46.
17. Kägi G, Bhatia KP, Telosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81:5-12.
18. Filippi L, Manni C, Pierantozzi M, Brusa L, Danieli R, Stanzione P, et al. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. Nucl Med Commun. 2005;26:421-6.
19. Matsui H, Nishinaka K, Oda M, Komatsu K, Kubori T, Udaka F. Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms? Parkinsonism Relat Disord. 2006;12:284-8.
20. Suzuki M, Urashima M, Oka H, Hashimoto M, Taira K. Cardiac sympathetic denervation in bradykinesia-dominant Parkinson's disease. Neuroreport. 2007;18:1867-70.
21. Spiegel J, Hellwig D, Farmakis G, Jost WH, Samnick S, Fassbender K, et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov Disord. 2007;22:1004-8.
22. Hakusui S, Yasuda T, Yanagi T, Tohyama J, Hasegawa Y, Koike Y, et al. A radiological analysis of heart sympathetic functions with meta-[123I] iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst. 1994;49:81-4.
23. Spiegel J, Möllers MO, Jost WH, Fuss G, Samnick S, Dillmann U, et al. FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov Disord. 2005;20:552-61.
24. Spiegel J, Hellwig D, Jost WH, Farmakis G, Samnick S, Fassbender K, et al. Cerebral and extracranial neurodegeneration are strongly coupled in Parkinson's Disease. Open Neurol J. 2007;1:1-4.
25. Schillaci O, Chiaravalloti A, Pierantozzi M, Di Pietro B, Koch G, Bruni C, et al. Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT. Int J Mol Med. 2011;28:881-6.
26. Ishibashi K, Saito Y, Murayama S, Kanemaru K, Oda K, Ishiwata K, et al. Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET. Eur J Nucl Med Mol Imaging. 2010;37:3-11.
27. Chiaravalloti A, Stefani A, Tavolozza M, Pierantozzi M, Di Biagio D, Olivola E, et al. Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson's disease: molecular imaging with 123I-MIBG. Mol Med Rep. 2012;6:1337-42.
28. Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med. 1999;40:917-23.
29. Saiki S, Hirose G, Sakai K, Kataoka S, Hori A, Saiki M, et al. Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci. 2004;220:105-11.
30. Schillaci O, Chiaravalloti A, Di Pietro B, Stefani A. Thalamic (123)I FP-CIT uptake in a patient with clinical diagnosis of Parkinson's disease and depression. Hell J Nucl Med. 2012;15:74-5.